IGC Pharma
35 hedge funds and large institutions have $2.27M invested in IGC Pharma in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
144% more capital invested
Capital invested by funds: $929K → $2.27M (+$1.34M)
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
25% more funds holding
Funds holding: 28 → 35 (+7)
2.1% more ownership
Funds ownership: 3.81% → 5.92% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$443K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$136K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.7K |
| 5 |
HF
HRT Financial
New York
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.7K |
| 2 |
Jane Street
New York
|
-$4.08K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$801 |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$152 |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$55 |
IGC Hedge Fund Activity: Q3 2025 in Review
35 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2025, worth a combined $2.27M — up 144% from $929K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IGC positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $443K. The largest seller was UBS Group, cutting an estimated $12.7K.
- 35 institutional investors held IGC Pharma (IGC) as of Q3 2025, up from 28 in Q2 2025.
- Funds reported $2.27M of IGC Pharma stock for Q3 2025, up 144% quarter-over-quarter.
- 9 funds opened new IGC Pharma positions in Q3 2025 and 2 closed out, a net change of +7 holders.
- The largest IGC Pharma buyer in Q3 2025 was Renaissance Technologies, an estimated $443K added.
- The largest IGC Pharma seller in Q3 2025 was UBS Group, an estimated $12.7K sold.
Based on aggregated 13F filings for Q3 2025.